Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Healthtrust
Accenture
Merck
Citi
Dow
Boehringer Ingelheim
Cipla
Harvard Business School

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022401

« Back to Dashboard

NDA 022401 describes TWYNSTA, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. Additional details are available on the TWYNSTA profile page.

The generic ingredient in TWYNSTA is amlodipine besylate; telmisartan. There are fifty drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the amlodipine besylate; telmisartan profile page.
Summary for 022401
Tradename:TWYNSTA
Applicant:Boehringer Ingelheim
Ingredient:amlodipine besylate; telmisartan
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 022401
Suppliers and Packaging for NDA: 022401
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0124 N 0597-0124-37
TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0125 N 0597-0125-37

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE;40MG
Approval Date:Oct 16, 2009TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE;40MG
Approval Date:Oct 16, 2009TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE;80MG
Approval Date:Oct 16, 2009TE:ABRLD:Yes

Expired US Patents for NDA 022401

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401-003 Oct 16, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401-001 Oct 16, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401-004 Oct 16, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim TWYNSTA amlodipine besylate; telmisartan TABLET;ORAL 022401-002 Oct 16, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Johnson and Johnson
Argus Health
Cerilliant
Express Scripts
Deloitte
Citi
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.